Sun Pharmaceutical Industries is currently trading at Rs. 474.05, up by 0.45 points or 0.10% from its previous closing of Rs. 473.60 on the BSE.
The scrip opened at Rs. 457.00 and has touched a high and low of Rs. 478.95 and Rs. 457.00 respectively. So far 167643 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 512.55 on 09-Jun-2020 and a 52 week low of Rs. 315.20 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 512.55 and Rs. 457.00 respectively. The current market cap of the company is Rs. 114328.31 crore.
The promoters holding in the company stood at 54.69%, while Institutions and Non-Institutions held 32.37% and 12.94% respectively.
Sun Pharmaceutical Industries has commenced Phase II clinical trial on AQCH, a phytopharmaceutical (plant derived) drug for treatment of COVID-19. The company has received approval from the Drugs Controller General of India (DCGI) for conducting Phase II clinical trial in April this year.
The clinical trial will be conducted across 12 centers in India in 210 patients. The treatment duration for patients will be 10 days. The results of the clinical trial are expected by October 2020. Human safety study of AQCH has already been completed and the drug has been found safe at the recommended dose for Phase II study.
The Drug has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with International Center for Genetic Engineering and Biotechnology (ICGEB), Italy.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.